Suppr超能文献

基于人或鼠免疫球蛋白E的介质释放试验在过敏原标准化中的应用。

Mediator release assays based on human or murine immunoglobulin E in allergen standardization.

作者信息

Kaul S, Lüttkopf D, Kastner B, Vogel L, Höltz G, Vieths S, Hoffmann A

机构信息

Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany.

出版信息

Clin Exp Allergy. 2007 Jan;37(1):141-50. doi: 10.1111/j.1365-2222.2006.02618.x.

Abstract

BACKGROUND

The biological potency of allergens can be measured by provoking mediator release from effector cells. As established immunochemical methods in allergen standardization only determine inhibition potency or major allergen content, routine tests for biological potency may enhance standardization and batch control of allergen products.

OBJECTIVE

The general performance and application potential of biological in vitro assays in batch control and standardization of allergens and as a tool for verifying activity and stability of allergen standards were analysed.

METHODS

Allergen extracts of five clinically relevant allergens from three to five different manufacturers were investigated. A CAP-IgE-inhibition assay was compared with mediator release assay (MRA)s based on murine or human basophils. Rat basophilic leukaemia (RBL) cells were passively sensitized with pooled murine allergen-specific IgE-containing sera. Humanized RBL cells and human-stripped basophils were sensitized with pooled patient's sera, which were also used for the CAP-IgE-inhibition assay. Allergen specificity of the sera was determined by immunoblotting.

RESULTS

A good batch-to-batch consistency was found with each assay among all manufacturers and allergens tested. Between different manufacturers, the products showed differences in activity and the various assays indicated an almost identical ranking. However, the biological assays revealed qualitative differences of biological activity or composition of allergen preparations undetectable by IgE-inhibition assay.

CONCLUSIONS

MRAs provide refined information on allergen activity, either confirming the results of IgE-inhibition assay, or indicating differences requiring further investigation, and represent a highly sensitive novel tool in allergen standardization. By using permanently cultivated cell lines, repeated venepuncture to obtain human basophils is avoided. As in the RBL assay, the coefficient of variation for the release values were below 15% and for the ED50 below 25%, the assay is suitable to determine differences that are relevant for batch control purposes.

摘要

背景

变应原的生物活性可通过激发效应细胞释放介质来测定。由于变应原标准化中既定的免疫化学方法仅能确定抑制活性或主要变应原含量,生物活性的常规检测可能会加强变应原产品的标准化和批次控制。

目的

分析生物体外检测在变应原批次控制和标准化中的总体性能及应用潜力,以及作为验证变应原标准品活性和稳定性工具的性能。

方法

研究了来自三至五个不同制造商的五种临床相关变应原的提取物。将CAP-IgE抑制试验与基于鼠或人嗜碱性粒细胞的介质释放试验(MRA)进行比较。用混合的含鼠变应原特异性IgE的血清对大鼠嗜碱性白血病(RBL)细胞进行被动致敏。用人源化RBL细胞和人脱颗粒嗜碱性粒细胞用混合患者血清致敏,该血清也用于CAP-IgE抑制试验。通过免疫印迹法测定血清的变应原特异性。

结果

在所有测试的制造商和变应原中,每种检测方法的批次间一致性良好。不同制造商之间的产品在活性上存在差异,各种检测方法显示出几乎相同的排名。然而,生物检测揭示了IgE抑制试验无法检测到的变应原制剂生物活性或成分的定性差异。

结论

MRA提供了有关变应原活性的精确信息,要么证实IgE抑制试验的结果,要么表明需要进一步研究的差异,并且是变应原标准化中一种高度敏感的新工具。通过使用永久培养的细胞系,避免了反复静脉穿刺获取人嗜碱性粒细胞。与RBL试验一样,释放值的变异系数低于15%,ED50低于25%,该试验适用于确定与批次控制目的相关的差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验